Maureen M Okam, MD, MPH
Associate Physician, Brigham and Women's Hospital|
Instructor in Medicine, Harvard Medical School
Associate Director, Brigham and Women’s Hospital Infusion Center
|Brigham and Women's Hospital|
Department of Medicine
75 Francis Street
Boston, MA 02115
Dr. Maureen M. Okam obtained her B Med. Sc (Anatomy) and MD degrees from the University of Port Harcourt, Nigeria, Hematology & Medical Oncology training at Yale School of Medicine and her Masters in Public Health from the Harvard School of Public Health. In 2005, she joined the faculty of Brigham and Women’s Hospital and is currently an Associate Physician in the Hematology Division. Dr. Okam's research interests span translational investigation, clinical trials and delivery of care to persons affected by hemoglobinopathies and other red cell disorders. Her current research focuses on the pre-clinical and clinical development of new agents for the treatment of hemoglobinopathies - sickle cell disease and thalassemia. Her on-going clinical evaluation of histone deacetylase inhibitors in the induction of fetal hemoglobin, is funded by the National Institutes of Health through a Harvard Blood Scholars research grant.
Okam MM, Mandell E, Hevelone N, Wentz R, Ross A, Abel GA. Comparative rates of adverse events with different formulations of intravenous iron. Am J Hematol. 2012 Nov; 87(11):E123-4.
Okam MM, Ebert BL. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors. Expert Rev Hematol. 2012 Jun; 5(3):303-11.
Harvard School of Public Health, 2008, MPH
Anemia, Sickle Cell
Pregnancy Complications, Hematologic
Publications (Pulled from Harvard Catalyst Profiles):
1. Okam MM, Shaykevich S, Ebert BL, Zaslavsky AM, Ayanian JZ. National trends in hospitalizations for sickle cell disease in the United States following the FDA approval of hydroxyurea, 1998-2008. Med Care. 2014 Jul; 52(7):612-8.
2. Field JJ, Lin G, Okam MM, Majerus E, Keefer J, Onyekwere O, Ross A, Campigotto F, Neuberg D, Linden J, Nathan DG. Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. Blood. 2013 Apr 25; 121(17):3329-34.
3. Okam MM, Mandell E, Hevelone N, Wentz R, Ross A, Abel GA. Comparative rates of adverse events with different formulations of intravenous iron. Am J Hematol. 2012 Nov; 87(11):E123-4.
4. Okam MM, Ebert BL. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors. Expert Rev Hematol. 2012 Jun; 5(3):303-11.
5. Styles L, Wager CG, Labotka RJ, Smith-Whitley K, Thompson AA, Lane PA, McMahon LE, Miller R, Roseff SD, Iyer RV, Hsu LL, Castro OL, Ataga KI, Onyekwere O, Okam M, Bellevue R, Miller ST. Refining the value of secretory phospholipase A2 as a predictor of acute chest syndrome in sickle cell disease: results of a feasibility study (PROACTIVE). Br J Haematol. 2012 Jun; 157(5):627-36.
6. Nathan DG, Field J, Lin G, Neuberg D, Majerus E, Onyekwere O, Keefer J, Okam M, Ross A, Linden J. Sickle cell disease (SCD), iNKT cells, and regadenoson infusion. Trans Am Clin Climatol Assoc. 2012; 123:312-7; discussion 317-8.
7. Lee AI, Okam MM. Anemia in pregnancy. Hematol Oncol Clin North Am. 2011 Apr; 25(2):241-59, vii.
8. Gladwin MT, Kato GJ, Weiner D, Onyekwere OC, Dampier C, Hsu L, Hagar RW, Howard T, Nuss R, Okam MM, Tremonti CK, Berman B, Villella A, Krishnamurti L, Lanzkron S, Castro O, Gordeuk VR, Coles WA, Peters-Lawrence M, Nichols J, Hall MK, Hildesheim M, Blackwelder WC, Baldassarre J, Casella JF. Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. JAMA. 2011 Mar 2; 305(9):893-902.
9. Ng S, Fanta C, Okam M, Bhatt AS. NK-cell and B-cell deficiency with a thymic mass. N Engl J Med. 2011 Feb 10; 364(6):586-8.
10. Okam M, Alsolaiman M, Brau A, Austin M, Plymyer M. Spontaneous pneumothorax as the first manifestation of lymphoma: a rare presentation and the importance of diagnostic biopsy. South Med J. 2003 Jan; 96(1):99-100.